Syndax Pharmaceuticals (SNDX) Tops Q4 EPS by 3c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.62), $0.03 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $0 versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance